Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. Given that PCSK9 binds to low-density lipoprotein (LDL ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The ...

Eli Lilly to acquire Verve Therapeutics for up to $1.3B SA News Tue, Jun. 17. Verve Therapeutics, Inc. SEC Filing - Quarterly Report (10-Q) May 14, 2025 SEC Filings Wed, May 14.

Review the current Eli Lilly and Co (LLY:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if LLY is the best investment for you.